Related Experiment Video
Updated: Jun 11, 2026
07:52
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Pathophysiological mechanisms contributing to renal dysfunction in chronic heart failure.
Kevin Damman1, Paul R Kalra, Hans Hillege
1Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Journal of Renal Care
|July 1, 2010
Summary
Chronic heart failure (CHF) frequently causes renal dysfunction, characterized by reduced glomerular filtration rate (GFR). This decline in kidney function is linked to higher mortality and morbidity, necessitating further research into underlying mechanisms and therapies.
Area of Science:
- Cardiology
- Nephrology
- Internal Medicine
Background:
- Renal dysfunction is a common complication in patients with chronic heart failure (CHF).
- Reduced glomerular filtration rate (GFR) in CHF patients is associated with increased mortality and morbidity.
- Shared risk factors like atherosclerosis, hypertension, and inflammation contribute to renal impairment in CHF.
Purpose of the Study:
- To explore the complex pathophysiological interactions between the heart and kidneys in CHF.
- To identify the key factors contributing to reduced GFR in CHF patients.
- To highlight the need for improved understanding to guide therapeutic interventions.
Main Methods:
- This study reviews existing literature on the relationship between CHF and renal dysfunction.
- It analyzes shared etiological risk factors and pathophysiological mechanisms.
- The review focuses on factors impacting glomerular filtration rate (GFR).
Main Results:
- Reduced GFR in CHF is strongly linked to adverse outcomes.
- Shared risk factors such as atherosclerosis, hypertension, endothelial dysfunction, and inflammation play a role.
- Interactions between cardiac and renal systems create a detrimental cycle.
Conclusions:
- Understanding the causes of reduced GFR in CHF is crucial for developing effective treatments.
- While reduced cardiac output is a factor, other elements like elevated central venous pressure and anemia may be treatable.
- Targeting these factors could potentially improve renal function and patient outcomes in CHF.
Related Concept Videos
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...